Treatment of XXXX with long-acting injectable @entity1090 : a 12-month open-label trial of the first long-acting second-generation antipsychotic.

@entity1 @entity308 @entity22 @entity148 @entity161 @entity716 @entity158 @entity21 @entity1090
BACKGROUND: The long-term safety and efficacy of long-acting injectable @entity1090 , the first long-acting second-generation antipsychotic, were evaluated in stable @entity1 with @entity161 . METHOD: After a 2-week run-in period during which @entity1 with DSM-IV @entity161 received flexible doses of 1 to 6 mg of oral @entity1090 , @entity1 received injections of 25 mg, 50 mg, or 75 mg of long-acting @entity1090 every 2 weeks for 12 months. Severity of @entity21 was assessed with the Extrapyramidal Symptom Rating Scale (ESRS), and efficacy was assessed with the Positive and Negative Syndrome Scale (PANSS). This study was conducted from March 29, 1999 to July 19, 2000. RESULTS: The subjects were 615 @entity1 with @entity161 who received at least 1 injection of long-acting @entity1090 . The 12-month trial was completed by 65% of @entity1 . Treatment was discontinued because of adverse events in 5% of @entity1 . @entity21 as adverse events were reported by 25% of the @entity1 . Severity of @entity21 (according to ESRS scores) was low at baseline and decreased in each of the groups during the 12 months. The other most common adverse events were @entity148 in 24%, @entity22 in 21%, @entity716 in 17%, and @entity308 in 14% of the @entity1 . @entity158 was associated with the injections. Severity of symptoms of @entity161 was improved in each group, with significant reductions in PANSS total scores (p <.01) and positive (p <.01) and negative (p <.001) factor scores. CONCLUSION: In terms of both safety and efficacy, symptomatically stable @entity1 with @entity161 benefit from being switched to long-acting injectable @entity1090 .
